dipyridamole has been researched along with Cancer of Pancreas in 8 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 6.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "(1) To determine the toxicity of an intensified postoperative adjuvant regimen for periampullary adenocarcinoma (pancreatic and nonpancreatic) utilizing concurrent 5-fluorouracil (5-FU), leucovorin (LV), dipyridamole (DPM), and mitomycin-C (MMC) combined with split-course locoregional external beam radiotherapy (EBRT) to 50 Gy." | 3.70 | Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Donehower, RC; Grochow, LB; Hruban, RH; Hurwitz, H; Jaffee, EM; Korman, LT; Lillemoe, KD; O'Reilly, S; Yeo, CJ; Zahurek, ML, 2000) |
| "Dipyridamole 75 mg was administered orally three times daily during the FU administration." | 2.73 | Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007) |
| "The use of neoadjuvant chemotherapy for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors, especially for patients with Stage IV b (Japan criteria)." | 1.32 | [Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics]. ( Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S, 2004) |
| "When dipyridamole and RA-233 were used alone, only weak to moderate effects were seen on RWP-2 tumor cell-induced platelet aggregation." | 1.29 | Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233. ( Agarwal, KC; Tzanakakis, GN; Vezeridis, MP, 1993) |
| "Determined by clonogenic assay in human colon cancer HT-29 cells, the cell survivals for AZT, 10 microM, dipyridamole, 5 microM, and methotrexate (MTX), 0." | 1.28 | Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. ( Taniki, T; Weber, G; Zhen, YS, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taoka, H | 1 |
| Hirano, H | 1 |
| Mitsui, Y | 1 |
| Umino, W | 1 |
| Nobuoka, Y | 1 |
| Yamashita, M | 1 |
| Tanigawa, K | 1 |
| Yoshimine, S | 1 |
| Imai, T | 1 |
| Kadowaki, S | 1 |
| Miyashita, K | 1 |
| Ikuma, H | 1 |
| Nakamura, T | 1 |
| Murata, T | 1 |
| Chen, P | 1 |
| Chien, PY | 1 |
| Khan, AR | 1 |
| Sheikh, S | 1 |
| Ali, SM | 1 |
| Ahmad, MU | 1 |
| Ahmad, I | 1 |
| Isacoff, WH | 1 |
| Bendetti, JK | 1 |
| Barstis, JJ | 1 |
| Jazieh, AR | 1 |
| Macdonald, JS | 1 |
| Philip, PA | 1 |
| Tzanakakis, GN | 1 |
| Agarwal, KC | 1 |
| Vezeridis, MP | 1 |
| Haaz, MC | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Renée, N | 1 |
| Etienne, MC | 1 |
| Milano, G | 1 |
| Burch, PA | 1 |
| Ghosh, C | 1 |
| Schroeder, G | 1 |
| Allmer, C | 1 |
| Woodhouse, CL | 1 |
| Goldberg, RM | 1 |
| Addo, F | 1 |
| Bernath, AM | 1 |
| Tschetter, LK | 1 |
| Windschitl, HE | 1 |
| Cobau, CD | 1 |
| Chakravarthy, A | 1 |
| Abrams, RA | 1 |
| Yeo, CJ | 1 |
| Korman, LT | 1 |
| Donehower, RC | 1 |
| Hruban, RH | 1 |
| Zahurek, ML | 1 |
| Grochow, LB | 1 |
| O'Reilly, S | 1 |
| Hurwitz, H | 1 |
| Jaffee, EM | 1 |
| Lillemoe, KD | 1 |
| Cameron, JL | 1 |
| Zhen, YS | 1 |
| Taniki, T | 1 |
| Weber, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma[NCT00003018] | Phase 2 | 54 participants (Actual) | Interventional | 1997-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for dipyridamole and Cancer of Pancreas
| Article | Year |
|---|---|
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipy | 2007 |
Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipyridamole; Female | 2000 |
6 other studies available for dipyridamole and Cancer of Pancreas
| Article | Year |
|---|---|
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc | 2004 |
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.
Topics: Animals; Antineoplastic Agents; Body Weight; Cardiolipins; Cell Proliferation; Deoxycytidine; Dipyri | 2006 |
Prevention of human pancreatic cancer cell-induced hepatic metastasis in nude mice by dipyridamole and its analog RA-233.
Topics: Adenosine; Animals; Dipyridamole; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Liver Ne | 1993 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2000 |
Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dipyridamole; DNA Replic | 1992 |